Ziprasidone (Geodon) and Ketamine Therapy | Tovani Health
Geodon (Ziprasidone) — Atypical antipsychotic
Verdict at Tovani Health
Compatible; QT prolongation is the main thing to monitor.
Ziprasidone and ketamine are compatible. The defining consideration for ziprasidone is QT-interval prolongation — it has the largest QT effect among the atypical antipsychotics. We get a baseline EKG and avoid stacking with other QT agents.
If you take Geodon regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Geodon interacts with ketamine
Ziprasidone antagonizes D2 and 5-HT2A receptors with significant QT prolongation. Must be taken with food (500+ calories) for absorption.
What we do at intake
Disclose dose and confirm you take it with food. Bring a baseline EKG. Tell us about any other QT-prolonging medications.
Bottom line
Ziprasidone and ketamine are compatible. The defining consideration for ziprasidone is QT-interval prolongation — it has the largest QT effect among the atypical antipsychotics. We get a baseline EKG and avoid stacking with other QT agents.
Frequently Asked Questions
Why is Geodon higher-risk than other atypicals for KAP?
The QT prolongation is meaningfully larger. Most patients tolerate it fine; we just want a baseline EKG before starting.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Geodon (Ziprasidone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Systematic review of pharmacodynamic interactions between ketamine and psychiatric medications used in depression treatment.
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Alnefeesi Y, Chen-Li D, Krane E, et al.. Journal of Psychiatric Research. 2022. PMID: 35688035
Meta-analysis of 2,665 patients across 79 studies — 45% response and 30% remission with ketamine in treatment-resistant depression.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.